InMode (INMD) Stock Overview
Designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
INMD Community Fair Values
See what 41 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
InMode Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.41 |
| 52 Week High | US$16.74 |
| 52 Week Low | US$12.72 |
| Beta | 2.12 |
| 1 Month Change | 4.50% |
| 3 Month Change | -13.30% |
| 1 Year Change | -1.10% |
| 3 Year Change | -57.23% |
| 5 Year Change | -62.61% |
| Change since IPO | 112.38% |
Recent News & Updates
INMD: Takeover Talks And Buyback Plan Will Shape A Measured Outlook
InMode's updated analyst price target remains at $15.00, with analysts pointing to small shifts in the discount rate, revenue growth assumptions, profit margin, and future P/E as the key drivers behind the reaffirmed valuation view. What's in the News Media report that InMode is in talks to be sold for about US$1.1b to a foreign investment fund, pointing to ongoing interest from financial buyers (Calcalist).INMD: Potential Takeover Talks And Buyback Plan Will Shape A Balanced Outlook
Analysts have maintained their $15.00 price target for InMode, citing small adjustments to assumptions such as the discount rate, revenue growth, profit margin, and future P/E that did not materially affect their overall valuation view. What's in the News Media reports indicate InMode is in talks to be sold for about US$1.1b to a foreign investment fund, highlighting ongoing interest from financial buyers (Calcalist).INMD: Potential Sale Talks And Buyback Plan Will Shape A Measured Outlook
Analysts have kept their $15.00 price target on InMode unchanged, citing only very small tweaks to model inputs around discount rate, revenue growth, profit margin and future P/E assumptions, rather than any major shift in their view of the stock. What's in the News Media report that InMode is in talks to be sold for about US$1.1 billion to a foreign investment fund, according to Calcalist (Calcalist).INMD: Potential Sale And Earnings Guidance Will Shape A Measured Forward View
Analysts have kept their $15.00 price target on InMode unchanged, citing only marginal tweaks to assumptions such as the discount rate, revenue growth, profit margin and future P/E that did not materially alter their overall view of the stock. What's in the News Calcalist reports that InMode is in talks to be sold for about US$1.1b to a foreign investment fund, indicating ongoing interest in potential ownership changes (Calcalist).Recent updates
Shareholder Returns
| INMD | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0.07% | -4.2% | 0.8% |
| 1Y | -1.1% | -18.5% | 27.8% |
Return vs Industry: INMD exceeded the US Medical Equipment industry which returned -18.5% over the past year.
Return vs Market: INMD underperformed the US Market which returned 27.8% over the past year.
Price Volatility
| INMD volatility | |
|---|---|
| INMD Average Weekly Movement | 4.5% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: INMD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: INMD's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 660 | Moshe Mizrahy | www.inmodemd.com |
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women’s health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions.
InMode Ltd. Fundamentals Summary
| INMD fundamental statistics | |
|---|---|
| Market cap | US$913.00m |
| Earnings (TTM) | US$93.83m |
| Revenue (TTM) | US$370.50m |
Is INMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INMD income statement (TTM) | |
|---|---|
| Revenue | US$370.50m |
| Cost of Revenue | US$79.53m |
| Gross Profit | US$290.97m |
| Other Expenses | US$197.14m |
| Earnings | US$93.83m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 06, 2026
| Earnings per share (EPS) | 1.48 |
| Gross Margin | 78.54% |
| Net Profit Margin | 25.33% |
| Debt/Equity Ratio | 0% |
How did INMD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/03 08:12 |
| End of Day Share Price | 2026/05/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
InMode Ltd. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Baird |
| Jeffrey Johnson | Baird |
| Travis Steed | Barclays |